Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 23, 2014

Primary Completion Date

November 8, 2017

Study Completion Date

March 14, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor

Selinexor orally as outlined in the study treatment arm.

DRUG

Liposomal doxorubicin

Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.

DRUG

Dexamethasone

Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

48201

Barbara Ann Karmanos Cancer Institute, Detroit

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER